253 related articles for article (PubMed ID: 31700623)
1. Immunostimulants in respiratory diseases: focus on Pidotimod.
Puggioni F; Alves-Correia M; Mohamed MF; Stomeo N; Mager R; Marinoni M; Racca F; Paoletti G; Varricchi G; Giorgis V; Melioli G; Canonica GW; Heffler E
Multidiscip Respir Med; 2019; 14():31. PubMed ID: 31700623
[TBL] [Abstract][Full Text] [Related]
2. Pidotimod: the state of art.
Ferrario BE; Garuti S; Braido F; Canonica GW
Clin Mol Allergy; 2015; 13(1):8. PubMed ID: 25999796
[TBL] [Abstract][Full Text] [Related]
3. Pidotimod: In-depth review of current evidence.
Mahashur A; Thomas PK; Mehta P; Nivangune K; Muchhala S; Jain R
Lung India; 2019; 36(5):422-433. PubMed ID: 31464215
[TBL] [Abstract][Full Text] [Related]
4. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.
Giagulli C; Noerder M; Avolio M; Becker PD; Fiorentini S; Guzman CA; Caruso A
Int Immunopharmacol; 2009 Nov; 9(12):1366-73. PubMed ID: 19712757
[TBL] [Abstract][Full Text] [Related]
5. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials.
Niu H; Wang R; Jia YT; Cai Y
Int Immunopharmacol; 2019 Feb; 67():35-45. PubMed ID: 30530167
[TBL] [Abstract][Full Text] [Related]
6. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression.
Carta S; Silvestri M; Rossi GA
Ital J Pediatr; 2013 May; 39():29. PubMed ID: 23663325
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.
Becker Y
Virus Genes; 2006 Oct; 33(2):235-52. PubMed ID: 16972040
[TBL] [Abstract][Full Text] [Related]
8. Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: A double blind randomized placebo-controlled study.
Mameli C; Pasinato A; Picca M; Bedogni G; Pisanelli S; Zuccotti GV;
Pharmacol Res; 2015 Jul; 97():79-83. PubMed ID: 25931316
[TBL] [Abstract][Full Text] [Related]
9. Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma.
Fu LQ; Li YL; Fu AK; Wu YP; Wang YY; Hu SL; Li WF
Mol Med Rep; 2017 Oct; 16(4):4151-4158. PubMed ID: 28731127
[TBL] [Abstract][Full Text] [Related]
10. Pidotimod: the past and the present.
Zuccotti GV; Mameli C
Ital J Pediatr; 2013 Dec; 39():75. PubMed ID: 24314100
[TBL] [Abstract][Full Text] [Related]
11. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections.
Zhao N; Liu C; Zhu C; Dong X; Liu X
Expert Rev Anti Infect Ther; 2019 Oct; 17(10):803-818. PubMed ID: 31603361
[No Abstract] [Full Text] [Related]
12. Metabolomic profile of children with recurrent respiratory infections.
Bozzetto S; Pirillo P; Carraro S; Berardi M; Cesca L; Stocchero M; Giordano G; Zanconato S; Baraldi E
Pharmacol Res; 2017 Jan; 115():162-167. PubMed ID: 27888158
[TBL] [Abstract][Full Text] [Related]
13. Pidotimod in the treatment of pediatric recurrent respiratory tract infection.
Li X; Li Q; Wang X; Lu M; Shen J; Meng Q
Pak J Med Sci; 2019; 35(4):981-986. PubMed ID: 31372128
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulating activity of Pidotimod in children with Down syndrome.
Zuccotti GV; Mameli C; Trabattoni D; Beretta S; Biasin M; Guazzarotti L; Clerici M
J Biol Regul Homeost Agents; 2013; 27(1):253-8. PubMed ID: 23489705
[TBL] [Abstract][Full Text] [Related]
15. Effects of Pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study.
Valentini D; Di Camillo C; Mirante N; Marcellini V; Carsetti R; Villani A
Ital J Pediatr; 2020 Mar; 46(1):31. PubMed ID: 32164747
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.
Zhao Y; Huang B; Huang S; Zheng H; Li YQ; Lun ZR; Shen J; Wang Y; Kasper LH; Lu F
Parasitol Res; 2013 Sep; 112(9):3151-60. PubMed ID: 23783399
[TBL] [Abstract][Full Text] [Related]
17. Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.
Lin SC; Cheng FY; Liu JJ; Ye YL
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670037
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulants revisited: focus on the pharmacology of Ribomunyl.
Portalès P; Clot J
BioDrugs; 2006; 20(2):81-4. PubMed ID: 16626165
[TBL] [Abstract][Full Text] [Related]
19. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease.
Singh M; Lee SH; Porter P; Xu C; Ohno A; Atmar RL; Greenberg SB; Bandi V; Gern J; Amineva S; Aminev A; Skern T; Smithwick P; Perusich S; Barrow N; Roberts L; Corry DB; Kheradmand F
J Allergy Clin Immunol; 2010 Jun; 125(6):1369-1378.e2. PubMed ID: 20430426
[TBL] [Abstract][Full Text] [Related]
20. TLR2, but not TLR4, is required for effective host defence against Chlamydia respiratory tract infection in early life.
Beckett EL; Phipps S; Starkey MR; Horvat JC; Beagley KW; Foster PS; Hansbro PM
PLoS One; 2012; 7(6):e39460. PubMed ID: 22724018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
